[Shanghai No. 1 Pharmaceutical Co., Ltd. 2025 Semi-Annual Performance Forecast](index=1&type=section&id=Shanghai%20No.%201%20Pharmaceutical%20Co.%2C%20Ltd.%202025%20Semi-Annual%20Performance%20Forecast) [Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast%20Overview) The company forecasts a significant year-on-year decrease in H1 2025 net profit attributable to shareholders due to prior year non-recurring gains, while core business net profit is projected to grow H1 2025 Performance Forecast | Indicator | H1 2025 Estimated (Ten Thousand RMB) | Year-on-Year Change | | :--- | :--- | :--- | | **Net Profit Attributable to Parent Company Shareholders** | 1,260 to 1,580 | ↓ 87.83% to 90.29% | | **Net Profit Excluding Non-Recurring Gains/Losses** | 800 to 1,000 | ↑ 10.59% to 38.24% | - This performance forecast data is a **preliminary estimate** by the company's finance department and has **not been audited** by a certified public accountant[4](index=4&type=chunk)[5](index=5&type=chunk) [Prior Period Performance Review](index=2&type=section&id=II.%20Prior%20Period%20Operating%20Performance%20and%20Financial%20Status) The H1 2024 review highlights a large disparity between reported net profit and net profit excluding non-recurring items, setting a high comparison base for the current period H1 2024 Financial Data | Indicator | H1 2024 Amount | | :--- | :--- | | Total Profit | 17,059.20 Ten Thousand RMB | | Net Profit Attributable to Parent Company Shareholders | 12,978.91 Ten Thousand RMB | | Net Profit Excluding Non-Recurring Gains/Losses | 723.37 Ten Thousand RMB | | Earnings Per Share | 0.5818 RMB | [Core Reasons for Performance Change](index=2&type=section&id=III.%20Main%20Reasons%20for%20Current%20Period%20Performance%20Change) The substantial year-on-year decline in net profit attributable to parent company shareholders is primarily due to a large, one-time housing expropriation compensation in the prior period - The primary reason for the decrease in net profit attributable to parent company shareholders is the **one-time housing expropriation compensation** in the prior period, resulting in a higher comparison base[7](index=7&type=chunk) [Risk Warning](index=2&type=section&id=IV.%20Risk%20Warning) The company states this performance forecast is a preliminary, unaudited estimate by the finance department, with final data potentially differing, but no other major uncertainties are identified - This performance forecast is a **preliminary calculation** by the company's finance department and has **not been audited** by a certified public accountant, thus it contains uncertainties[8](index=8&type=chunk) [Other Explanations](index=2&type=section&id=V.%20Other%20Explanatory%20Matters) The company reiterates that the forecast data is preliminary, and final accurate financial data will be based on the officially disclosed 2025 semi-annual report, advising investor caution - Final financial data will be subject to the company's **officially disclosed 2025 semi-annual report**; investors are advised to be aware of investment risks[9](index=9&type=chunk)

Core Points - The announcement details the election results of the employee director for Shanghai First Pharmaceutical Co., Ltd, with Mr. Hu Liangyu elected as the employee director for the 11th Board of Directors [1] - Mr. Hu Liangyu will serve alongside eight non-employee directors elected at the 2024 annual general meeting, with the term lasting until the end of the 11th Board's tenure [1] Summary by Sections - **Election Results** - Mr. Hu Liangyu has been elected as the employee director for the 11th Board of Directors [1] - The election was conducted in accordance with the Company Law and the company's articles of association [1] - **Director's Profile** - Mr. Hu Liangyu, born in 1980, is a Chinese national with no permanent residency abroad and holds a bachelor's degree [3] - He has held various positions including Secretary of the Youth League Committee at Shanghai Bailian Group and is currently the Deputy Secretary of the Party Committee, Discipline Inspection Commission Secretary, and Chairman of the Labor Union at the company [3] - Mr. Hu has no relationships with the company's directors, senior management, controlling shareholders, or actual controllers, and does not hold any shares in the company [3] - He meets the qualifications to serve as a director of a listed company and has not faced any penalties from the China Securities Regulatory Commission or stock exchanges [3]

Meeting Overview - The shareholders' meeting of Shanghai First Pharmaceutical Co., Ltd. was held on June 20, 2025, at the company's office in Shanghai [1] - The meeting was presided over by Chairman Zhang Haibo and utilized a combination of on-site and online voting methods, complying with relevant laws and regulations [1][3] - A total of 50.2559% of the shares were represented at the meeting [1] Voting Results - A total of 12 proposals were reviewed during the meeting, with proposals 1-7, 9-12 passing by a simple majority, while proposal 8, a special resolution, passed with over two-thirds of the votes [3] - The voting results for the proposals showed a high level of agreement among shareholders, with the majority of votes for each proposal exceeding 99% [2][3] - For example, proposal 1 received 111,862,784 votes in favor, representing 99.7759% of the votes [1][2] Legal Compliance - The meeting's procedures, attendance, and voting processes were confirmed to be in accordance with the Company Law, Securities Law, and other relevant regulations [3][4] - The legal opinions provided by the attending lawyers confirmed the legality and validity of the resolutions passed during the meeting [3][4]

Core Viewpoint - The legal opinion letter confirms the legality and validity of the procedures, qualifications, proposals, and voting results of the 2024 annual general meeting of Shanghai First Pharmaceutical Co., Ltd. [1][5] Group 1: Meeting Organization - The 2024 annual general meeting is scheduled for June 20, 2025, at the third meeting room on the 20th floor of 681 Xiaomuqiao Road, Xuhui District, Shanghai [1][2] - The meeting was announced on May 31, 2025, on the Shanghai Stock Exchange website, detailing the time, location, agenda, attendees, registration methods, and voting procedures [2][3] Group 2: Meeting Attendance - A total of 2 shareholders and their representatives attended the meeting, holding 100,278,034 shares with voting rights, which represents a significant portion of the total voting shares [3][4] - Additionally, 116 shareholders participated through the online voting system during the designated trading hours on June 20, 2025 [4] Group 3: Meeting Proposals - The meeting included several key proposals such as the 2024 Board of Directors' work report, 2024 Supervisory Board's work report, financial reports, profit distribution plan, and various resolutions regarding board member elections and compensation [4][5] - Proposals related to the financial service agreement with Bailian Group and the cancellation of the Supervisory Board were also discussed [4] Group 4: Voting Procedures and Results - The voting results indicated that proposals requiring a two-thirds majority were approved, while others needed a simple majority, with specific votes counted separately for minority investors [5] - The legal opinion confirms that all voting procedures and results comply with relevant laws and regulations, ensuring the legitimacy of the meeting outcomes [5]

Core Points - The company held its first temporary meeting of the 11th Board of Directors on June 20, 2025, with all directors present and no dissenting votes [1][2] - Zhang Haibo was elected as the Chairman of the 11th Board of Directors, with a term starting from the approval date until the end of the board's term [1] - Yao Jun was elected as the Vice Chairman of the 11th Board of Directors, with a similar term duration [1] - The composition of the specialized committees of the 11th Board of Directors was approved, including the Audit Committee, Strategy and ESG Committee, Compensation and Assessment Committee, and Nomination Committee, with all members receiving unanimous support [2] Summary by Categories Board Elections - Zhang Haibo was elected as Chairman with unanimous approval from all 9 directors [1] - Yao Jun was elected as Vice Chairman, also receiving unanimous support [1] Committee Composition - The Audit Committee will consist of Tang Songlian (Chair), Li Jinbiao, Wang Feng, and Chen Shaoxiong [2] - The Strategy and ESG Committee will include Zhang Haibo (Chair), Yao Jun, Zhou Yu, Li Jinbiao, Wang Feng, Tang Songlian, and Chen Shaoxiong [2] - The Compensation and Assessment Committee will be led by Chen Shaoxiong (Chair), with members Zhou Yu, Zhang Rui, Wang Feng, and Tang Songlian [2] - The Nomination Committee will be chaired by Wang Feng, including Zhang Haibo, Hu Liangyu, Tang Songlian, and Chen Shaoxiong [2]

证券代码：600833 证券简称：第一医药 公告编号：临 2025-032 上海第一医药股份有限公司 关于职工董事选举结果的公告 2 上海第一医药股份有限公司董事会 2025 年 6 月 21 日 1 附件：胡良玉先生简历 胡良玉，男，1980 年出生，中国国籍，无境外永久居留权，本科，高级政工师，中 共党员。曾任上海百联集团股份有限公司团委书记，百联集团有限公司团委副书记、团 委书记，本公司第十届监事会职工监事等职务。现任本公司党委副书记、纪委书记、工 会主席、第十一届董事会职工董事。 除已披露的信息外，胡良玉先生与公司的董事、高级管理人员、公司控股股东、实 际控制人不存在关联关系，未持有公司股份。胡良玉先生不存在《公司法》中规定的不 得担任公司董事的情形；未受过中国证监会和证券交易所任何处罚和惩戒，任职资格符 合担任上市公司董事的条件。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 根据《公司法》《公司章程》的有关规定，上海第一医药股份有限公司（以下简称 "公司"）职工代表大会选举胡良玉先生为公司第十一届董事会职工董事 ...

上海市金茂律师事务所 上海第一医药股份有限公司（以下简称"公司"）2024 年年度股东大会（以 下简称"本次股东大会"）于 2025 年 6 月 20 日在上海市徐汇区小木桥路 681 号 20 楼第三会议室召开。上海市金茂律师事务所经公司聘请委派韩春燕律师、 路遥律师（以下简称"本所律师"）出席会议，就本次股东大会的召集、召开程 序，出席会议人员资格，会议议案，以及会议的表决程序、表决结果等发表法律 意见。 本法律意见书根据《中华人民共和国公司法（2023 修订）》（以下简称"《公 司法》"）、《中华人民共和国证券法（2019 修订）》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《上海证券交易所 上市公司自律监管指引第 1 号——规范运作（2025 年 5 月修订）》（以下简称 "《自律监管指引 1 号》"）等有关法律、法规和规范性文件以及《上海第一医 药股份有限公司章程》（以下简称"《公司章程》"）而出具。 为出具本法律意见书，本所审查了公司本次股东大会的有关文件和材料。本 所得到公司如下保证，即其已提供了本所认为出具本法律意见书所必需的材料， 所提供的原始材料、副 ...

证券代码：600833 证券简称：第一医药 公告编号：2025-030 上海第一医药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 6 月 20 日 (二)股东大会召开的地点：上海市徐汇区小木桥路 681 号 20 楼第三会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 118 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 112,114,065 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 50.2559 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由公司董事长张海波先生主持。会议采用现场投票及网络投票相结合的 方式表决，符合《公司法》等有关法律、法规及《公司章程》的有关规定。 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2025-031 第十一届董事会第一次（临时）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示：本次董事会不存在否决议案，没有董事投反对/弃权票。 上海第一医药股份有限公司（以下简称"公司"）第十一届董事会第一次（临时） 会议于 2025 年 6 月 20 日下午在上海市徐汇区小木桥路 681 号 20 楼第三会议室召开。 全体董事同意本次会议免于提前 5 日通知。本次会议应参加表决董事为 9 名，委托表决 0 名，实际参加表决董事 9 名。会议的召开符合有关法律、行政法规、部门规章、规范 性文件和《公司章程》的规定，会议形成的决议合法、有效。 根据会议议程，本次会议审议通过以下事项： 上海第一医药股份有限公司 一、公司《关于选举第十一届董事会董事长的议案》 选举张海波先生为公司第十一届董事会董事长，任期自本次董事会审议通过之日起 至公司第十一届董事会届满为止。 表决结果：赞成 9 名，反对 0 名，弃权 0 名 二、公司《关于选举第十一届董 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2025-033 上海第一医药股份有限公司 第十一届董事会第二次（临时）会议决议公告 表决结果：赞成 9 名，反对 0 名，弃权 0 名 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示：本次董事会不存在否决议案，没有董事投反对/弃权票。 上海第一医药股份有限公司（以下简称"公司"）第十一届董事会第二次（临时） 会议于 2025 年 6 月 20 日下午在上海市徐汇区小木桥路 681 号 20 楼第三会议室召开。 全体董事同意本次会议免于提前 5 日通知。本次会议应参加表决董事为 9 名，委托表决 0 名，实际参加表决董事 9 名。会议的召开符合有关法律、行政法规、部门规章、规范 性文件和《公司章程》的规定，会议形成的决议合法、有效。 根据会议议程，本次会议审议通过以下事项： 一、公司《关于聘任总经理的议案》 聘任姚军先生（简历附后）为公司总经理，任期自本次董事会审议通过之日起至公 司第十一届董事会届满之日止。 表决结果：赞成 9 名，反对 0 名，弃 ...